1. Home
  2. RVPH vs ANVS Comparison

RVPH vs ANVS Comparison

Compare RVPH & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVPH
  • ANVS
  • Stock Information
  • Founded
  • RVPH 2006
  • ANVS 2008
  • Country
  • RVPH United States
  • ANVS United States
  • Employees
  • RVPH N/A
  • ANVS N/A
  • Industry
  • RVPH Biotechnology: Pharmaceutical Preparations
  • ANVS Biotechnology: Pharmaceutical Preparations
  • Sector
  • RVPH Health Care
  • ANVS Health Care
  • Exchange
  • RVPH Nasdaq
  • ANVS Nasdaq
  • Market Cap
  • RVPH 88.0M
  • ANVS 92.6M
  • IPO Year
  • RVPH N/A
  • ANVS 2020
  • Fundamental
  • Price
  • RVPH $2.09
  • ANVS $2.95
  • Analyst Decision
  • RVPH Strong Buy
  • ANVS Strong Buy
  • Analyst Count
  • RVPH 5
  • ANVS 6
  • Target Price
  • RVPH $11.40
  • ANVS $29.67
  • AVG Volume (30 Days)
  • RVPH 1.8M
  • ANVS 548.9K
  • Earning Date
  • RVPH 11-14-2024
  • ANVS 03-31-2025
  • Dividend Yield
  • RVPH N/A
  • ANVS N/A
  • EPS Growth
  • RVPH N/A
  • ANVS N/A
  • EPS
  • RVPH N/A
  • ANVS N/A
  • Revenue
  • RVPH N/A
  • ANVS N/A
  • Revenue This Year
  • RVPH N/A
  • ANVS N/A
  • Revenue Next Year
  • RVPH N/A
  • ANVS N/A
  • P/E Ratio
  • RVPH N/A
  • ANVS N/A
  • Revenue Growth
  • RVPH N/A
  • ANVS N/A
  • 52 Week Low
  • RVPH $0.60
  • ANVS $2.88
  • 52 Week High
  • RVPH $4.83
  • ANVS $20.00
  • Technical
  • Relative Strength Index (RSI)
  • RVPH 60.41
  • ANVS 20.82
  • Support Level
  • RVPH $1.78
  • ANVS $2.99
  • Resistance Level
  • RVPH $2.15
  • ANVS $5.50
  • Average True Range (ATR)
  • RVPH 0.15
  • ANVS 0.34
  • MACD
  • RVPH 0.02
  • ANVS -0.18
  • Stochastic Oscillator
  • RVPH 88.30
  • ANVS 3.59

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.

About ANVS Annovis Bio Inc.

Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.

Share on Social Networks: